This site is intended for healthcare professionals. If you are a patient or caregiver, please contact your physician to discuss clinical trial eligibility.

Pipeline Overview

Explore our pipeline of investigational medicines, featuring therapies designed to inhibit cancer-driving molecular targets in genetically defined pediatric and adult patient populations.

Investigational Program Preclinical Phase 1 Phase 2 Registration

Larotrectinib (LOXO-101)

Cancers Harboring Alterations of Tropomyosin Receptor Kinase (TRK)

Adult Phase 1 Trial

Status: Continue to follow enrolled TRK fusions patients; currently enrolling

Phase 2 Basket Trial

Status: Adult/adolescent solid tumors with TRK fusions, currently enrolling

Pediatric Phase 1/2 Trial

Status: Pediatric solid or primary CNS tumors with TRK fusions, currently enrolling

LOXO-195 (TRK inhibitor)

Cancers Harboring Alterations of TRK With Potential Acquired Resistance

LOXO-195 Phase 1/2 Trial

Status: Phase 1/2 trial currently enrolling

LOXO-292 (RET inhibitor)

Cancers Harboring Alterations of Rearranged During Transfection (RET) Kinase

LOXO-292 Phase 1 Trial

Status: Phase 1 trial currently enrolling

LOXO-305 (BTK inhibitor)

B-cell Cancers Harboring an Acquired Bruton's Tyrosine Kinase (BTK) C481S Mutation

 

Status: IND-enabling studies ongoing for an expected clinical trial initiation in 2018

FGFR Program

Cancers Harboring Alterations of Fibroblast Growth Factor Receptor (FGFR) Kinase

 

Status: Lead Optimization

For comprehensive details about these clinical trials, please refer to clinicaltrials.gov.

Policy for Access to Investigational Agents

Loxo Oncology is committed to helping patients who have not responded to available therapies and may benefit from its investigational therapies. Loxo Oncology's Policy for Access to Investigational Agents describes the principles and government regulations that the company will follow when considering a request.

globe

Sites are enrolling
all around the globe.

Find a Clinical Trial